secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0000950170-22-007377
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q1 cash $641.7M, rev $18.4M; FT596+R-CHOP IND, FT536 solid tumor on track
--------------------------------------------------------------------------------

- Q1 2022 revenue of $18.4M from Janssen/Ono collaborations; R&D expense $72.1M, G&A $20.7M.
- Cash, equivalents and investments $641.7M as of March 31, 2022.
- FT596+R-CHOP clinical protocol for first-line aggressive lymphoma to be submitted to FDA in 2Q22.
- FT536 CAR MICA/B NK cell product candidate on track for first patient treatment in 2Q22.
- Third IND candidate nominated under Janssen collaboration triggering preclinical milestone payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022007377/0000950170-22-007377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022007377/fate-20220504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer